Our vision at Alzheon
We strive to bring transformational therapies to patients.
Passion
We are passionately dedicated to developing effective treatments for Alzheimer’s disease and other devastating neurodegenerative disorders.
Innovation
We are applying innovation to drug development in neurodegeneration by capitalizing on scientific and clinical insights, so we can rapidly and efficiently move towards new therapeutic solutions with substantially lower development risk.
Patients
We are committed to improving the lives of patients, their families and caregivers.
Impact
We aim to develop breakthrough therapies that can change the lives of patients with neurodegenerative disorders.
Our approach
Applying precision medicine to Alzheimer’s
Right Patients: APOE4/4 Early Alzheimer’s
- Focus on Early Alzheimer’s where amyloid oligomers play key role in disease progression
Right Drug: Improved valiltramiprosate/ALZ-801 oral prodrug formulation
- Consistent plasma levels allow for high brain penetration for oligomer inhibition
- Improved oral absorption & GI tolerability
- No increase in vasogenic brain edema in over 3,000 Alzheimer’s patient data set
Right Trial: Phase 3 trial to confirm clinical efficacy in APOE4/4 patients
- Phase 3 program with validated cognitive & functional measures
- Well tolerated, long-term safety evaluated in 3,000 patients at effective clinical dose
- Fast Track designation granted by U.S. FDA for valiltramiprosate Alzheimer’s program in 2017
For patients and caregivers
Enrollment has completed in our APOLLOE4 Phase 3 clinical trial evaluating oral tablet valiltramiprosate.
Click here for more information at ClinicalTrials.gov
Enrollment has completed in our Phase 2 biomarker study evaluating oral tablet valiltramiprosate.
Click here for more information.
Valiltramiprosate/ALZ-801 is an investigational product in clinical development, and its use has not been approved by the FDA or EMA.